Development of an improved high specific activity tin-117m-DTPA product was initiated at Isotherapeutics Group, an experienced radiopharmaceutical development company contracted by Serene for this and numerous previous projects. FDA IND approval is expected in  2Q23, with subsequent continuation of Phase 2 clinical trials through the NIH Experimental Therapeutics program.